Why Inhibrx’s Recent Strength May Not Be Built to Last

Inhibrx (NASDAQ:INBX) has staged a sharp rally after reporting positive topline results from its registrational trial of Ozekibart (INBRX-109) back in October 2025. The stock surged more than 150% in a short span, drawing significant investor attention. However, when the move is examined through the lens of the Adhishthana framework, a structural risk begins to surface, particularly when analysing the stock's positioning on the monthly cycle.

Read the full article on Benzinga for deeper insights into the Adhishthana Cycle, the stock’s recent trajectory, and expert commentary.